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The efficacies of dicationic carbazole compounds, nitazoxanide (NTZ), and paromomycin were evaluated
against the AUCp1 isolate of Cryptosporidium parvum by using a neonatal mouse model. Compounds were
solubilized or suspended in deionized water and administered orally by gavage to neonatal mice at a constant
dose rate on days 0 to 5 (treatment started on day 0). Dose rates varied for individual carbazole compounds
but ranged from 0.65 to 20 mg/kg of body weight. NTZ was tested at 100 and 150 mg/kg, and paromomycin was
tested at 50 mg/kg. Efficacies were determined by comparing numbers of oocysts present in treated versus
control mice at necropsy examination on day 6. Demonstrable efficacy was observed for several carbazole
compounds, based on significant reductions in the numbers of oocysts recovered from treated mice versus
control mice. Compounds 1, 7, and 10 (19.0 mg/kg) reduced oocyst passage in treated mice to less than 5% of
that in control mice. Treatment with compounds 6, 8, and 9 (17.0 mg/kg) resulted in reductions of oocyst output
to less than 10% of that in controls. Although they were not comparable in efficacy to compounds 1, 6, 7, 8, 9,
and 10, treatment with other carbazole compounds resulted in statistically significant reductions in oocyst
output in treated versus control mice. Compound 1 retained efficacy resulted in reduction of oocyst output to
approximately 6% of that in controls when the dose was reduced to 5 mg/kg. Further reductions in the dose rate
resulted in considerable reductions in anticryposporidial activity. Likewise, the efficacies of compounds 9 and
10 were reduced substantially when the doses were lowered to one-half the screening dose. Paromomycin
yielded excellent activity (reduction of oocyst output to <2% of that in controls) at a dose of 50 mg/kg. NTZ
yielded moderate efficacy as powder and injectable formulations administered at 100 mg/kg orally (reduction
of oocyst output to 42 and 26% of that in controls, respectively). Oral administration of the injectable
formulation of NTZ at a dose of 150 mg/kg resulted in improved efficacy (oocyst output, <5% of that in controls).
Cryptosporidiosis is a ubiquitous diarrheal disease of ani-
mals and humans (6, 10). The causative agent, Cryptosporidium
parvum, infects a wide variety of mammalian hosts (10). Its
broad host range, together with its refractoriness to most com-
mon antiparasitics and disinfectants, has led to its character-
ization as one of the more important emerging disease agents
of the latter two decades. Cryptosporidiosis in immunocompe-
tent humans results in acute, but self-limiting, gastroenteritis.
However, in persons with compromised or nonfunctional im-
mune systems, the disease can be protracted and even life-
threatening and can involve multiple organ systems. Crypto-
sporidiosis is also emerging as a major water-borne disease in
humans (21). Despite considerable efforts to identify and de-
velop effective cryptosporidicidal agents, none has as yet re-
ceived regulatory approval for treatment or prevention of hu-
man or animal cryptosporidiosis (3, 19).
In studies reported elsewhere (2, 4) we have identified ef-
fective cryptosporidicidal compounds among a class of chem-
ical agents known as aromatic dicationic molecules. Although
prototype dications such as pentamidine and diminazene often
demonstrated undesirable toxic effects, molecules currently
under development in our laboratories appear to possess en-
hanced efficacies against a broader range of parasites and re-
duced toxicity or a complete lack of toxicity. The broad spec-
trum of activity of some of these dicationic compounds is
noteworthy and includes intracellular and extracellular proto-
zoa, Pneumocystis carinii, Cryptococcus neoformans, Mycobac-
terium spp., and certain viruses (2, 3–5, 7, 9, 15, 20, 23–26). The
purpose of this report is to summarize cryptosporidicidal ac-
tivities of selected dicationic carbazole compounds determined
by use of our neonatal mouse model (2, 4, 16). In addition, we
sought to compare the efficacies of the carbazoles, particularly
compound 1, to that of nitazoxanide (NTZ) (8, 18) and paro-
momycin (11–13, 17).
MATERIALS AND METHODS
Chemistry of the carbazole compounds. The synthesis of carbazoles 1 to 5, 7,
10 to 14, and 16 to 18 and of the dinitrile precursors of carbazoles 6 and 9 has
been described previously (20). The synthesis of carbazoles 8 and 15 will be
described in a future manuscript. Compounds 6 and 9 were prepared by Pinner
syntheses (23) from their respective dinitrile precursors. For dose calculations,
compounds were presumed to have a purity of 100% (wt/wt).
General experimental methods. Uncorrected melting points were measured
on a Thomas Hoover capillary melting-point apparatus. 1H nuclear magnetic
resonance (NMR) spectra were recorded on Varian XL 400 MHz spectrometers
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in dimethyl sulfoxide (DMSO)-d6. Anhydrous ethanol was distilled over Mg
immediately prior to use. Reactions were monitored by infrared spectrometry
(Nujol mull; Perkin-Elmer 1320 spectrophotometer) or by reverse-phase high-
pressure liquid chromatography (HPLC). HPLC chromatograms were recorded
as previously described (20) with the following modifications. A Dupont Zorbax
Rx C8 column (3.0 mm by 15 cm; diameter, 3.5 mm) was used. Mobile phases
consisted of mixtures of acetonitrile (3.75 to 67.5% [vol/vol]) in water containing
tetramethylammonium chloride, sodium heptanesulfonate, and phosphate buffer
(pH 2.5) (10 mM each). The concentration of acetonitrile was maintained at
3.75% for 0.5 min, increased to 45% following a linear gradient over 12.5 min,
increased immediately to 67.5% following a linear gradient over 3 min, then
maintained at 67.5% for 4.5 min. Fast atom bombardment mass spectra (FAB-
MS) were recorded on a VG 70-SEQ Hybrid spectrometer (cesium ion gun; 30
kV). Microanalyses were performed by Atlantic Microlab, Norcross, Ga., and
were within 60.4% of calculated values.
3,6-Bis(N-hydroxyamidino)carbazole hemimaleate hydrochloride (compound
6). A suspension of 3,6-dicyanocarbazole (2.18 g, 10.0 mmol) and anhydrous
ethanol (5.0 ml, 85 mmol) in 1,4-dioxane (150 ml) was saturated with hydrogen
chloride at 0°C. The reaction mixture was stirred at room temperature for 34
days before the crude diimidate was filtered off and suspended in anhydrous
ethanol (10 ml). An ethanolic solution of hydroxylamine, prepared by treating a
solution of the hydrochloride salt (7.00 g, 101 mmol) in hot ethanol (100 ml) with
sodium ethoxide (21% [wt/wt] solution in denatured alcohol, 37 ml, 99 mmol)
and filtering off the resultant sodium chloride, was added, and the mixture was
stirred at reflux for 2 h. The reaction mixture was concentrated, and the crude
product was filtered off. Purification was effected sequentially. The crude product
was initially treated with excess maleic acid in aqueous ethanol, followed by
precipitation of the crude maleate salt with ether. Then an aliquot of the maleate
salt was treated with aqueous HCl, followed by precipitation of the hydrochloride
salt with acetone. Finally, the maleic acid treatment described above was re-
peated to give a white solid as the hemimaleate hydrochloride salt (0.34 g; 7.8%):
melting point .300°C (dec.); 1H NMR d 12.23 (s, 1 H), 10.8 (br s, 1 H), 8.60 (s,
2 H), 8.4 (v br s, 2 H), 7.81 (d, J 5 8.8 Hz, 2 H), 7.70 (d, J 5 8.8 Hz, 2 H), 6.14
(s, 2 H); FAB-MS m/z 284 (MH1 of free base); HPLC tR 9.23 min (93.5 area %).
Calculated for C14H13N5O2¥HCl¥C4H4O4: C, 49.61; H, 4.16; N, 16.07; Cl, 8.13.
Found: C, 49.36; H, 4.19; N, 15.91; Cl, 8.02.
Synthesis of 2,7-bis(N-isopropylamidino)carbazole dihydrochloride (com-
pound 9). 2,7-Dicyanocarbazole (1.74 g, 8.03 mmol) and anhydrous ethanol (5.0
ml, 86 mmol) were added to 1,4-dioxane (100 ml) saturated with hydrogen
chloride. After 4 days the crude diimidate (2.93 g) was filtered off and suspended
in dry ethanol (20 ml). Freshly distilled isopropylamine (10 ml, 120 mmol) was
added, and the mixture was stirred overnight at room temperature. The excess
amine was distilled off, the reaction mixture was diluted with ether, and the crude
product was filtered off. A filtered (Celite) solution of the crude product in hot
water was treated with NaOH solution to precipitate out the free base. The base
was converted back to the dihydrochloride salt by treatment with aqueous HCl.
Recrystallization from water-isopropyl alcohol gave a pale yellow powder (1.58 g;
48.3%): melting point .330°C; 1H NMR (400 MHz, DMSO-d6) d 12.54 (s, 1 H),
9.71 (d, J 5 7.9 Hz, 2 H), 9.57 (s, 2 H), 9.21 (s, 2 H), 8.48 (d, J 5 8.0 Hz, 2 H),
7.98 (s, 2 H), 7.57 (dd, J 5 8.0 and 1.6 Hz, 2 H), 4.15 (m, 2 H), 1.32 (d, J 5 6.3
Hz, 12 H); FAB-MS m/z 336 (MH1 of free base); HPLC tR 11.36 min (96.7 area
%). Calculated C20H25N5A2HClA0.4H2O: C, 57.80; H, 6.74; N, 16.85; Cl,
17.06. Found: C, 57.75; H, 6.67; N, 16.69; Cl, 17.08.
2-Acetyloxy-N-[(5-nitro-2-thiazolyl)] benzamide (NTZ). The powder formula-
tion of NTZ was obtained from Romark Laboratories, Tampa, Fla. The percent-
age of active NTZ in the powder formulation was 70.8%. The injectable formu-
lation of NTZ was obtained from Blue Ridge Pharmaceuticals, Greensboro, N.C.
The percentage of active NTZ in the injectable formulation was 20.0%.
O-2-Amino-2-deoxy-a-D-gluco-pyranosyl-(134)-O-[O-2,6-diamino-2,6-dideoxy-
b-L-idopyranosyl-(133)-b-D-ribofuranosyl-(135)]-2-deoxy-D-streptamine (paro-
momycin). Paromomycin was obtained from Sigma Chemical Co., St. Louis, Mo.
The percentage of active paromomycin in the formulation was $99.9%. The
structures of all test compounds are shown in Tables 1 and 2.
Neonatal mouse model. ICR Swiss mice were purchased from a commercial
supplier and delivered to Auburn University as females with 2-day-old litters.
Neonatal mice were individually weighed and cross-fostered to females to yield
groups of 8 to 10 litters (8 to 12 suckling mice) with approximately equal mean
body weights. Females (with litters) were individually housed in plastic box cages
containing ground corncobs as bedding and were provided a commercial labo-
ratory block ration and water ad libitum. All test compounds were administered
to neonatal mice in each of two litters (8 to 12 mice/litter 3 2 litters 5 16 to 24
mice per compound). Two litters of mice received the diluent in which drugs
were solubilized or dispersed and thus served as nontreated controls (see below).
Doses of carbazole compounds were determined initially by solubility character-
istics of the compounds. Subsequently, however, we used data from related
compounds to establish a screening dose of 17.0 mg/kg of body weight. Multiple
dosages were evaluated for compounds 1, 9, and 10 (see Table 1 and Fig. 1).
Paromomycin was evaluated at 50 mg/kg. The initial dosage of 100 mg/kg for
NTZ was determined by communication with the AIDS Branch of the National
Institutes of Health and the supplier of the drug. Subsequent dosages were based
on preliminary efficacies obtained in the model.
On the morning of day 0, prior to the start of treatments, mice in each litter
were inoculated orally by gavage with 1 3 105 or 2 3 105 oocysts of the AUCp1
isolate of C. parvum (2). Four hours after infection with C. parvum oocysts, each
mouse received the first treatment with test compound. Treatments were re-
peated once daily for 5 additional days (six total treatments). Drugs were solu-
bilized or suspended in deionized water or in a solution of 1% DMSO in
deionized water. The concentration of compound in the diluent was calculated to
yield the screening dosage when 10 ml of solution or suspension was administered
to a 3-g mouse. We could then increase or decrease the dosage by increasing or
decreasing the volume of drug administered. The purpose of these procedures
was to maintain a constant dose rate throughout the study. Control mice received
diluent that did not contain drug at a volumetric rate identical to that for treated
animals.
All mice were euthanized by cervical dislocation on day 6. Necropsies, recov-
ery of oocysts, and efficacy evaluations were conducted as previously described
(2).
Statistical analyses. Mean numbers of oocysts recovered from treated and
control mice were compared by the nonparametric Wilcoxon Mann-Whitney
test. In each instance, a probability level of P , 0.05 was considered significant.
RESULTS AND DISCUSSION
Compound numbers, names, screening doses, and efficacies
are presented in Tables 1 and 2. The mean raw hemacytometer
oocyst count in diluent-treated mice was 133.1. Counts ranged
from 25.7 to 241.5 (standard error [SE] 5 12.7). Demonstrable
efficacy was observed for several carbazole compounds, based
on significant reductions in the numbers of oocysts recovered
from treated mice versus control mice. Compounds 1, 7, and 10
(19.0 mg/kg) reduced oocyst passage in treated mice to less
than 5% of that in control mice. Treatment with compounds 6,
8, and 9 (17.0 mg/kg) resulted in reductions of oocyst output to
less than 10% of that in controls. Although they were not
comparable in efficacy to the compounds mentioned above,
treatment with carbazoles 2, 12, 14, and 18 resulted in statis-
tically significant reductions in oocyst output in treated versus
control mice (Table 1). Treatment with other compounds (i.e.,
compounds 3, 11, 15, and 17) resulted in numerical but not
statistically significant reductions in oocyst counts. Compound
1 retained an efficacy resulting in reduction of oocyst counts to
6% of those in controls when the dose was reduced to 5 mg/kg.
Further reductions in the dose resulted in considerable reduc-
tions in anticryposporidial activity (Fig. 1). Likewise, the effi-
cacies of compounds 9 and 10 were reduced considerably when
the dose was lowered to one-half the screening dose rate.
Treatment with some carbazole compounds (e.g., compounds
4, 5, 13, and 16) resulted in no demonstrable numerical reduc-
tions in recovered oocysts. Compound 1 is currently under
evaluation in other animal models. Paromomycin yielded ex-
cellent activity (,2% of the oocyst output in controls) at the
screening dose of 50 mg/kg. Treatment with NTZ as a powder
or as an injectable formulation administered orally yielded
moderate efficacy (42 or 26% of the oocyst output in controls,
respectively [Table 2]). Oral administration of the injectable
formulation at a dose of 150 mg/kg resulted in a much higher
efficacy (,5% of the oocyst output in controls [Table 2]).
We have previously reported the efficacies of pentamidine
analogs and diaryl furans against C. parvum (2, 4). However,
this is our first report on the efficacies of dicationic carbazole
compounds against C. parvum. Not only did we demonstrate
substantial efficacies for certain carbazoles, but we also
achieved efficacies with certain carbazoles comparable to or
exceeding those of paromomycin and NTZ, in both cases at
considerably lower doses. The survival and consistent weight
gains of treated mice support the safety of the carbazole com-
pounds at the dosages tested.
Compound 1 appears to be the most potent of the effective
anticryptosporidial carbazole compounds. Doses of 5.0 mg/kg
or more resulted in reductions in oocyst recovery to 6.1% of
that in controls or less. Interestingly, increased efficacy was not
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TABLE 1. Efficacies of dicationic carbazoles against C. parvum in the neonatal mouse model
Compound
no. Compound name Chemical structure
Dose




1 2,7-Diamidinocarbazole dihydrochloride 19.0c 0.8 6 0.3d
2 2,7-Bis(2-imidazolinyl)-9-methylcarbazole
dihydrochloride
20.0 50.3 6 3.2d
3 2,7-Bis[5-(2-imidazolinyl)-2-benzimidizoyl]
carbazole tetrahydrochloride
20.0 63.5 6 7.0
4 2-(2-Imidazolinyl)-7-methoxycarbazole
hydrochloride
17.0 102.9 6 9.9
5 2-(2-Imidazolinyl)-7-methoxy-9-
methycarbazole hydrochloride
17.0 129.0 6 12.8
6 3,6-Bis(N-hydroxyamidine)carbazole
hemimaleate hydrochloride
17.0 5.6 6 0.9d
7 3,6-Diamidino-9-methylcarbazole
dihydrochloride
17.0 3.0 6 0.4d
8 2,6-Diamidinocarbazole dihydrochloride 17.0 6.9 6 1.1d
9 2,7-Bis(N-isopropylamidino)carbazole
dihydrochloride
8.5 30.5 6 5.0d
17.0 9.1 6 1.6d
10 3,6-Diamidinocarbazole dihydrochloride 9.5 28.7 6 4.6d
19.0 2.2 6 0.5d




no. Compound name Chemical structure
Dose






20.0 94.6 6 11.3
12 3,6-Bis(2-imidazolinyl)carbazole
dihydrochloride
20.0 34.8 6 7.4d
13 3,6-Bis[5-(2-imidazolinyl)-2 benzimidazoyl]
carbazole tetrahydrochloride
16.4 125.5 6 13.3
14 2,7-Bis (2-imidazolinyl)carbazole
dihydrochloride
14.3 54.4 6 10.7d
15 3,6-Bis(N-isopropyl-amidino)-9-carboxy-
methylcarbazole dihydrochloride
17.0 55.3 6 6.2
16 3,6-Bis(2-imidazolinyl)-9-cyclohexylmethyl
carbazole dihydrochloride
17.0 108.5 6 9.2
17 3,6-Bis[2-(1,4,5,6-tetrahydropyrimidinyl)]-9-
methylcarbazole dihydrochloride
17.0 90.8 6 10.5
18 3,6-Bis(2-imidazolinyl)-9-methylcarbazole
dihydrochloride
17.0 36.9 6 4.3d
a Mice were treated at a constant dose rate daily for 6 days.
b Mean numbers of oocysts in treated mice are expressed as percentages of the mean number of oocysts recovered from control mice (taken as 100%).
c See Fig. 1 for dosage titration of compound 1.
d Treated mice and control mice were significantly different (P # 0.05).
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observed when the dose was increased from 9.5 to 19.0 mg/kg.
In other evaluations (4), we have also identified a diaryl furan
with excellent activity against C. parvum. In that report, doses
of 17.0 and 8.5 mg/kg had efficacies resulting in oocyst reduc-
tion to 5.1 and 6.4% of levels in nontreated controls, respec-
tively. It appears that the potency of compound 1 in the present
study exceeds that of the diaryl furan.
Our results for paromomycin corroborate efficacies observed
against C. parvum in other animal models and in cell cultures
(11–13, 17). The effective dose reported here (50 mg/kg) was
less than the effective doses reported in other murine models.
This could be because most other murine models use chemical
immunosuppression to induce and maintain C. parvum infec-
tions. Higher doses may be required in such models (e.g., rats)
or against established infections. The regimen reported here is
a prophylactic regimen because compounds are administered
approximately 4 h after infection and before establishment of
substantial numbers of developmental stages in the intestinal
tract.
This is apparently the first published report of the evaluation
of NTZ against C. parvum in a mouse model. Our data are
based on the use of two formulations. The powder formulation
was moderately effective against C. parvum when tested at 100
mg/kg. These results were probably due to the poor solubility
of the drug in an aqueous diluent. Poor solubility could result
in clumping in the intestinal lumen and reduced availability of
the test compound. This explanation is supported by our re-
sults following oral administration of an injectable formulation
of NTZ, because improved efficacy (26 versus 42% of the
oocyst output in the controls [Table 2]) was obtained with this
formulation by using the same dose rate. This is further sup-
ported by substantial improvement in efficacy (4.3% of the
oocyst output in the controls) when the dose was increased to
150 mg/kg. The observed lack of toxicity of the dicationic
carbazoles and paromomycin in this study is likely the result of
poor absorption following oral administration. This was ini-
tially perceived as a limitation in the use of the carbazoles as
FIG. 1. Dosage titration of compound 1 against C. parvum in HsD/ICR Swiss
mice.
TABLE 2. Efficacies of NTZ and paromomycin against C. parvum in the neonatal mouse model






100.0c 42.3 6 4.6d
100.0e 26.0 6 4.5d







50.0 1.2 6 0.6d
a Mice were treated at a constant dose rate daily for 6 days.
b Mean numbers of oocysts in treated mice are expressed as percentages of the mean number of oocysts recovered from control mice (taken as 100%).
c Oral formulation.
d Treated mice and control mice were significantly different (P # 0.05).
e Injectable formulation administered orally.
f This dosage appeared moderately toxic; 14 of 25 mice survived the treatment period.
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antimicrobial agents. However, in the case of intestinal cryp-
tosporidiosis, absorption following oral administration is prob-
ably not necessary for activity against cryptosporidial stages in
the intestinal tract. Our results support this presumption.
The anticryptosporidial mechanism of action of the dicat-
ionic carbazoles is not known with certainty. However, we do
know that many of the dicationic-substituted aromatic mole-
cules bind to the minor groove of DNA. We presume that
DNA binding of these molecules plays a substantial role in
many cases in their antimicrobial activity by inhibiting either
DNA-associated enzymes such as topoisomerases (1) or endo-
and exonucleases (14) or other processes, such as DNA repli-
cation, recombination, and repair.
Although numerous drugs have demonstrated activity
against Cryptosporidium, none has received regulatory ap-
proval for treatment of either human or animal cryptosporidi-
osis. In the present report, we demonstrate the efficacies of a
new class of dicationic molecules and confirm the efficacies of
NTZ and paromomycin against experimental C. parvum infec-
tions in our neonatal mouse model. Results reported here
indicate that the safety and efficacy of compound 1 either is
comparable to or exceeds the safety and efficacies of other
anticryptosporidial agents that have been evaluated in other
models. Our current efforts focus on further evaluation of
compound 1. Although efficacies obtained with certain com-
pounds in our model appear to correlate with results obtained
in humans (e.g., with paromomycin), confirmation of the effi-
cacies of compound 1 and other dicationic carbazoles against
cryptosporidiosis in humans awaits the results of efficacy stud-
ies in humans.
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